Observational studyActa dermato-venereologica2025
Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice.
Observational study in Acta dermato-venereologica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Long-Term Disease Control During Continuous Treatment with Upadacitinib and Baricitinib for Moderate-to-Severe Atopic Dermatitis: a Real-World Monocentric Retrospective Study.Dermatology and therapy · 2026Article
- Patient Experience and Preferences for Treatments in Atopic Dermatitis.Dermatology and therapy · 2026Article
- Real-World Use of Abrocitinib for Moderate-to-Severe Atopic Dermatitis in the United States Based on Electronic Health Records and Administrative Claims.Advances in therapy · 2026Article
- Real-World Effectiveness, Safety, and 36-Month Persistence of Upadacitinib in Elderly Patients with Moderate-to-Severe Atopic Dermatitis: The 3-6 Month Critical Window and the Role of Early Itch Response and Psychotropic Medication Use.Journal of clinical medicine · 2026Article
- Early Clinical Response Predicts Treatment Persistence in Advanced Therapy-naive Atopic Dermatitis.Acta dermato-venereologica · 2026Article
- Dupilumab versus tralokinumab in atopic dermatitis: A propensity score adjusted comparison from BioDay.Journal of the European Academy of Dermatology and Venereology : JEADV · 2026Article
- Longitudinal Response Trajectories with Dupilumab or Upadacitinib in Moderate-to-Severe Atopic Dermatitis: A Multicentre Real-World Study: IL-AD (Italian Landscape Atopic Dermatitis).Dermatology and therapy · 2026Article
- Atopic dermatitis.Nature reviews. Disease primers · 2026Review
- Drug Survival in Atopic Dermatitis: Comparison of Biologics and JAK Inhibitors in the BioDay Registry.Allergy · 2026Article
- Review
- Efficacy and safety of dupilumab following discontinuation of JAK inhibitors in patients with moderate-to-severe atopic dermatitis: a single-center retrospective study.Frontiers in immunology · 2026Article
- Real-World Use of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia: A Single-Centre Retrospective Descriptive Analysis.Clinical, cosmetic and investigational dermatology · 2026Article
- Two-Year Efficacy and Safety of Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis: A Long-Term Extension (ADjoin).Dermatology and therapy · 2025Article
- Anti-Inflammatory Therapies for Atopic Dermatitis: A New Era in Targeted Treatment.Journal of clinical medicine · 2025Review
- Efficacy and safety of JAK inhibitors in patients aged > 60 years with moderate-to-severe atopic dermatitis: a 52-week multicenter, real-life study-IL AD (Italian Landscape Atopic Dermatitis).Archives of dermatological research · 2025Article
- Innovations and Emerging Therapies in Atopic Dermatitis Part 1.Current treatment options in allergy · 2025Article
- Beyond the blockade: unmet needs in systemic targeted atopic dermatitis therapy.Frontiers in immunology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, several new systemic agents (biologics and Janus kinase inhibitors [JAKi]) have been registered for the treatment of moderate-to-severe atopic dermatitis (AD). However, comparisons of real-world drug survival data and insights into treatment patterns of these advanced systemics are limited. Data from a prospective observational single-centre registry were collected from 549 adult AD patients (759 treatment courses) receiving biologics (dupilumab, tralokinumab) or JAKi (abrocitinib, baricitinib, upadacitinib) and analysed using Kaplan-Meier survival curves. Cox regression analyses were used to evaluate predictors of survival. Frequencies and percentages summarized data on the initial and subsequent treatments received, with a Sankey diagram illustrating the switching patterns. The 18-month overall drug survival rates for dupilumab, abrocitinib, upadacitinib, tralokinumab, and baricitinib were 70.0%, 51.5%, 48.4%, 39.4%, and 20.4%, respectively. No significant predictors for drug survival were identified. Dupilumab was the predominant initial treatment (87.2%) and upadacitinib the most frequently used second and third treatment. In the total cohort, 57.9% of patients remained on their initial treatment and 26.8% switched to other treatments. In conclusion, dupilumab showed superior survival rates while baricitinib had the lowest survival rate. Frequent switching highlights the need for biomarkers that predict response to advanced systemic treatments to improve attrition rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.